THe use of macrolides and corticosteroids as immunomodulators in community-acquired pneumonia
The mortality rate in community-acquired pneumonia (CAP) has remained high. A single episode of pneumonia has an increased mortality rate across all age groups v. controls. Research continues to find ways to decrease the mortality rate associated with pneumonia. Corticosteroids and macrolides have been shown to influence inflammation; their immunomodulatory effect decreases the production of inflammatory cytokines. Their use in CAP is proposed to improve mortality and morbidity. However, controversy over their use has been evident in several trials. Recent trials have shown that beta lactam antibiotic use without a macrolide is non-inferior and that corticosteroid use only confers a mortality benefit in patients requiring ionotropic support. In one study, corticosteroid use reduced hospital stay by 1 day, but had no effect on mortality. The regular use of macrolides and corticosteroids solely as immunomodulators in CAP cannot be advocated at this stage.
Alan Peter, Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa
Full Text:PDF (217KB)
Cite this article
Date published: 2016-12-19
Full text views: 218
- There are currently no refbacks.
African Journal of Thoracic and Critical Care Medicine| Online ISSN: 2617-0205
Our Journals: South African Medical Journal | African Journal of Health Professions Education | South African Journal of Bioethics and Law | South African Journal of Child Health | Southern African Journal of Critical Care | South African Respiratory Journal | South African Journal of Obstetrics and Gynaecology |